356 related articles for article (PubMed ID: 16248830)
41. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit.
Papaetis GS; Orphanidou D; Panagiotou TN
Curr Drug Targets; 2011 Sep; 12(10):1498-512. PubMed ID: 21675944
[TBL] [Abstract][Full Text] [Related]
42. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
Kudzma DJ
Am J Manag Care; 2002 Oct; 8(16 Suppl):S472-82. PubMed ID: 12408410
[TBL] [Abstract][Full Text] [Related]
43. Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra.
Whitehead JP
Int J Biochem Cell Biol; 2011 Aug; 43(8):1071-4. PubMed ID: 21558015
[TBL] [Abstract][Full Text] [Related]
44. [PPAR receptors and insulin sensitivity: new agonists in development].
Pégorier JP
Ann Endocrinol (Paris); 2005 Apr; 66(2 Pt 2):1S10-7. PubMed ID: 15959400
[TBL] [Abstract][Full Text] [Related]
45. Glitazones: clinical effects and molecular mechanisms.
Stumvoll M; Häring HU
Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692
[TBL] [Abstract][Full Text] [Related]
46. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function.
Borchert M; Schöndorf T; Lübben G; Forst T; Pfützner A
Diabetes Technol Ther; 2007 Oct; 9(5):410-20. PubMed ID: 17931049
[TBL] [Abstract][Full Text] [Related]
47. The Clinical Significance of PPAR Gamma Agonism.
Campbell IW
Curr Mol Med; 2005 May; 5(3):349-63. PubMed ID: 15892654
[TBL] [Abstract][Full Text] [Related]
48. Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: insights from models of obesity and type 2 diabetes.
Boelsterli UA; Bedoucha M
Biochem Pharmacol; 2002 Jan; 63(1):1-10. PubMed ID: 11754868
[TBL] [Abstract][Full Text] [Related]
49. [Role of PPARγ, a transcription factor in cardiovascular disease].
Mukohda M
Nihon Yakurigaku Zasshi; 2019; 154(2):56-60. PubMed ID: 31406043
[TBL] [Abstract][Full Text] [Related]
50. X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs.
Rajapaksha H; Bhatia H; Wegener K; Petrovsky N; Bruning JB
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1981-1991. PubMed ID: 28499821
[TBL] [Abstract][Full Text] [Related]
51. Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Tanabe J; Tamasawa N; Yamashita M; Matsuki K; Murakami H; Matsui J; Sugimoto K; Yasujima M; Suda T
Diabetes Obes Metab; 2008 Sep; 10(9):772-9. PubMed ID: 17970759
[TBL] [Abstract][Full Text] [Related]
52. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
53. [PPARs: physiological functions and pharmacological roles of agonists in human diseases. Note II].
Filip-Ciubotaru F; Manciuc C; Grigore C; Foia L
Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):240-7. PubMed ID: 23077903
[TBL] [Abstract][Full Text] [Related]
54. PPARγ signaling and emerging opportunities for improved therapeutics.
Wang S; Dougherty EJ; Danner RL
Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
[TBL] [Abstract][Full Text] [Related]
55. Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Quinn CE; Hamilton PK; Lockhart CJ; McVeigh GE
Br J Pharmacol; 2008 Feb; 153(4):636-45. PubMed ID: 17906687
[TBL] [Abstract][Full Text] [Related]
56. [Mechanisms of action of thiazolidinediones].
Girard J
Diabetes Metab; 2001 Apr; 27(2 Pt 2):271-8. PubMed ID: 11452221
[TBL] [Abstract][Full Text] [Related]
57. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.
Park KS; Ciaraldi TP; Lindgren K; Abrams-Carter L; Mudaliar S; Nikoulina SE; Tufari SR; Veerkamp JH; Vidal-Puig A; Henry RR
J Clin Endocrinol Metab; 1998 Aug; 83(8):2830-5. PubMed ID: 9709955
[TBL] [Abstract][Full Text] [Related]
58. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
Gelman L; Feige JN; Desvergne B
Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
[TBL] [Abstract][Full Text] [Related]
59. [PPAR family and its relationship to metabolic syndrome].
Zhang XY; Chen LH; Guan YF
Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
[TBL] [Abstract][Full Text] [Related]
60. Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.
Karsdal MA; Henriksen K; Genovese F; Leeming DJ; Nielsen MJ; Riis BJ; Christiansen C; Byrjalsen I; Schuppan D
Diabetologia; 2017 Jan; 60(1):50-59. PubMed ID: 27631136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
